No Data
Qianxin Biotechnology-B (02509.HK): The supplemental application for QX001S (LexinFintech, ustekinumab injection) for pediatric plaque psoriasis has been approved.
On March 3, 2023, Glonghui announced that Chuanxin Biology-B (02509.HK) received the "Approval Notice for Supplementary Application for Pharmaceutical" issued by the National Medical Products Administration (NMPA) on March 3, 2025. The supplementary application for QX001S, which adds the indication for pediatric plaque psoriasis, has been approved. QX001S is a biosimilar of the original product Stelara (ustekinumab injection), and its mechanism of action is to block the binding of the shared p40 subunit of IL-12 and IL-23 to the IL-12Rβ1 receptor protein on the surface of target cells, thereby inhibiting.
CICC: AI + finance is expected to迎来 a scaling inflection point.
The equalization of AI technology continues, and the financial IT Industry has clear enabling scenarios, with the potential to achieve a transition from "tool empowerment" to "Asia Vets restructuring."
Flows Into Financials Sustaining Momentum – Stocks With High SA Quant Ratings
Shares of US-listed Chinese Stocks Are Trading Lower After Wall Street Had Its Worst Session of the Year on Friday, Driven by Inflation Concern and Mixed Economic Data. Also, Weakness May Be Due to Profit-taking After Rallying Last Week.
Chip Stocks With the Best Momentum Going Into Nvidia Earnings
Express News | DeepSeek announces open sourcing of five projects next week.
